PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2673162-0 1989 Phenytoin-induced improvement in muscle cramping and insulin action in three patients with the syndrome of insulin resistance, acanthosis nigricans, and acral hypertrophy. Phenytoin 0-9 insulin Homo sapiens 53-60 35238273-11 2022 The present study, therefore, revealed that the PT-PM-Insulin-wafer group might have very promising applications for wound healing. Phenytoin 48-50 insulin Homo sapiens 54-61 16527842-0 2006 Diphenylhydantoin suppresses glucose-induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets. Phenytoin 0-17 insulin Homo sapiens 45-52 16527842-1 2006 Diphenylhydantoin (DPH), which is clinically used in the treatment of epilepsy, inhibits glucose-induced insulin release from pancreatic islets by a mechanism that remains unknown. Phenytoin 0-17 insulin Homo sapiens 105-112 16527842-1 2006 Diphenylhydantoin (DPH), which is clinically used in the treatment of epilepsy, inhibits glucose-induced insulin release from pancreatic islets by a mechanism that remains unknown. Phenytoin 19-22 insulin Homo sapiens 105-112 16527842-2 2006 In the present study, DPH is shown to suppress glucose-induced insulin release concentration-dependently. Phenytoin 22-25 insulin Homo sapiens 63-70 16527842-4 2006 DPH also suppressed insulin release in the presence of 16.7 mm glucose, 200 microm diazoxide, and 30 mm K+ without affecting the intracellular Ca2+ concentration. Phenytoin 0-3 insulin Homo sapiens 20-27 1838051-0 1991 Phenytoin-induced insulin insensitivity. Phenytoin 0-9 insulin Homo sapiens 18-25 1838051-5 1991 In vitro studies of phenytoin in a primary culture system of adipocytes that allowed assessment of both insulin receptor binding and post-binding function showed a 57% reduction in maximum [14C]3-0-methylglucose transport in the presence of phenytoin while having no effect on maximum insulin binding. Phenytoin 20-29 insulin Homo sapiens 104-111 1838051-6 1991 These results suggest that phenytoin administration can result in insulin insensitivity by inducing a post-binding defect in insulin action. Phenytoin 27-36 insulin Homo sapiens 66-73 1838051-6 1991 These results suggest that phenytoin administration can result in insulin insensitivity by inducing a post-binding defect in insulin action. Phenytoin 27-36 insulin Homo sapiens 125-132 2673162-0 1989 Phenytoin-induced improvement in muscle cramping and insulin action in three patients with the syndrome of insulin resistance, acanthosis nigricans, and acral hypertrophy. Phenytoin 0-9 insulin Homo sapiens 107-114 2673162-1 1989 Phenytoin sodium has been used to treat muscle cramps of diverse causes, and is known to increase insulin sensitivity during long-term use. Phenytoin 0-16 insulin Homo sapiens 98-105 643721-0 1978 [Insulin secretion in obese patients treated with diphenylhydantoin (DPH)]. Phenytoin 50-67 insulin Homo sapiens 1-8 643721-0 1978 [Insulin secretion in obese patients treated with diphenylhydantoin (DPH)]. Phenytoin 69-72 insulin Homo sapiens 1-8 596101-1 1977 The effect of short-term treatment with diphenylhydantoin (DPH) on the insulin secretion patterns during OGTT and on the daily insulin profile was studied in obese patients. Phenytoin 40-57 insulin Homo sapiens 71-78 596101-1 1977 The effect of short-term treatment with diphenylhydantoin (DPH) on the insulin secretion patterns during OGTT and on the daily insulin profile was studied in obese patients. Phenytoin 59-62 insulin Homo sapiens 71-78 596101-2 1977 DPH treatment for 3 days with a dose of 300 mg/die (100 mg, 3 times daily) significantly decreased the insulin release after glucose ingestion, but did not alter the basal insulin level. Phenytoin 0-3 insulin Homo sapiens 103-110 596101-4 1977 A smaller decrease of plasma free fatty acid concentration during OGTT performed after DPH administration confirmed the inhibitory effect of the drug on insulin release. Phenytoin 87-90 insulin Homo sapiens 153-160 596101-5 1977 Short-term DPH treatment was also shown to decrease markedly the postpradial insulin release in obese patients. Phenytoin 11-14 insulin Homo sapiens 77-84 942132-0 1976 [Effect of tolbutamide on plasmatic insulin and glucose in children treated with diphenylhydantoin (author"s transl)]. Phenytoin 81-98 insulin Homo sapiens 36-43 812019-0 1975 Alimentary reactive hypoglycemia: effects of DBI and dilantin on insulin secretion. Phenytoin 53-61 insulin Homo sapiens 65-72 1118088-0 1975 Effects of diuril and dilantin on blood glucose and insulin levels in late pregnancy. Phenytoin 22-30 insulin Homo sapiens 52-59 4359748-0 1974 The effect of diphenylhydantoin on insulin response. Phenytoin 14-31 insulin Homo sapiens 35-42 4206393-0 1973 Effect of diphenylhydantoin on insulin response in the oral glucose tolerance test in children and adolescents. Phenytoin 10-27 insulin Homo sapiens 31-38 4710447-0 1973 Plasma glucose and insulin responses to oral glucose with chronic diphenylhydantoin therapy. Phenytoin 66-83 insulin Homo sapiens 19-26 4558084-0 1972 Comparison of the inhibitory effects of diphenylhydantoin and diazoxide upon insulin secretion from the isolated perfused pancreas. Phenytoin 40-57 insulin Homo sapiens 77-84 4918328-0 1970 The in vitro inhibition of insulin secretion by diphenylhydantoin. Phenytoin 48-65 insulin Homo sapiens 27-34 4918328-2 1970 Because of this association between DPH and hyperglycemia, the effect of DPH on insulin release in vitro using preparations of isolated islets of Langerhans and pancreatic pieces was examined. Phenytoin 73-76 insulin Homo sapiens 80-87 4918328-3 1970 In concentrations identical with those considered necessary for adequate anticonvulsant therapy in man, DPH markedly decreases the insulin secretory response of pancreatic pieces to methacholine, 1 mug/ml, tolbutamide, 250 mug/ml, and glucose, 200 mg/100 ml, without any demonstrable alteration in the oxidative conversion of glucose-1-(14)C or glucose-6-(14)C to (14)CO(2) by isolated islets. Phenytoin 104-107 insulin Homo sapiens 131-138 7040499-1 1982 The effects of a loading dose of 15 mg/kg phenytoin by iv infusion on the serum levels of insulin, glucagon, and glucose were investigated in five fasting healthy male volunteers between the ages of 23 and 35 years. Phenytoin 42-51 insulin Homo sapiens 90-97 7040499-2 1982 Serum glucose concentrations rose immediately after the infusion of phenytoin followed by a significant increase in serum insulin values (P less than 0.05). Phenytoin 68-77 insulin Homo sapiens 122-129 6994939-2 1980 While receiving DPH, insulin response to glucose was less than that in the control group, both in absolute terms and when related to the blood glucose level. Phenytoin 16-19 insulin Homo sapiens 21-28 6994939-4 1980 One month after cessation of DPH, the plasma insulin response had returned to the levels found in the control group, and glucose tolerance had improved to be significantly better than that found in the control group. Phenytoin 29-32 insulin Homo sapiens 45-52 6994939-5 1980 Thus, the tendency of DPH to impair the insulin response to glucose has been confirmed in this controlled study. Phenytoin 22-25 insulin Homo sapiens 40-47 4120665-0 1973 Effect of diphenylhydantoin on plasma-insulin in insulinoma. Phenytoin 10-27 insulin Homo sapiens 38-45 5008555-0 1972 Effect of diphenylhydantoin on insulin secretion in man. Phenytoin 10-27 insulin Homo sapiens 31-38 4918328-4 1970 This DPH-induced inhibition of insulin secretion is not reversed by higher concentrations of glucose (600 mg/100 ml) or by increasing concentrations of extracellular calcium ion (4-6 mmoles/liter). Phenytoin 5-8 insulin Homo sapiens 31-38 4918328-6 1970 60 mM potassium ion, on the other hand, not only restores the insulin secretory response to glucose (200 mg/100 ml) but results in an added stimulation of insulin secretion in the presence of DPH. Phenytoin 192-195 insulin Homo sapiens 155-162 4904710-0 1970 Inhibition of insulin secretion by diphenylhydantoin in the isolated perfused pancreas. Phenytoin 35-52 insulin Homo sapiens 14-21